Immunoglobulin E and bullous pemphigoid

被引:37
|
作者
Cozzani, Emanuele [1 ]
Gasparini, Giulia [1 ]
Di Zenzo, Giovanni [2 ]
Parodi, Aurora [1 ]
机构
[1] Univ Genoa, Di S Sal, Dermatol Sect, San Martino Policlin Hosp, I-16132 Genoa, Italy
[2] IDI IRCCS, Mol & Cell Biol Lab, Fdn Luigi Maria Monti, Rome, Italy
关键词
bullous pemphigoid; Th2; anti-BP230 and anti-BP180 IgE; omalizumab; FC-EPSILON-RI; LINKED-IMMUNOSORBENT-ASSAY; MEMBRANE ZONE ANTIBODIES; SERUM IGE LEVELS; BLISTER FLUID; MAST-CELLS; DISEASE-ACTIVITY; AUTOIMMUNE-DISEASE; CIRCULATING IGE; ELEVATED LEVELS;
D O I
10.1684/ejd.2018.3366
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Clinical features and histological findings in bullous pemphigoid (BP) suggest a Th2-oriented inflammatory reaction, especially in the early stages of the disease. Elevated total serum IgE levels, blood eosinophilia, and elevated serum levels of different soluble inflammatory Th2 response mediators have been described in large cohorts of patients with classic clear-cut BP manifestations. Direct immunofluorescence, indirect immunofluorescence, and anti-BP230 and anti-BP180 IgE ELISA testing show self-reactive IgE autoantibodies in a consistent number of BP patients. Both IgE autoantibodies and a Th2-oriented immune response may play a role in the initial phases of BP and atypical cases of BP, such as severe erythematous and urticarial forms of BP, as well as blister formation. Two recently reported experimental murine models employing IgE autoantibodies against BP180 have been reported and the successful treatment of bullous pemphigoid with the anti-IgE antibody, omalizumab, supports the roles played by IgE autoantibodies in BP pathogenesis.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 50 条
  • [21] Childhood bullous pemphigoid treated by i.v. immunoglobulin
    Xiao, Ting
    Li, Bo
    Wang, Ya-Kun
    He, Chun-Di
    Chen, Hong-Duo
    JOURNAL OF DERMATOLOGY, 2007, 34 (09) : 650 - 653
  • [22] Cytokines and bullous pemphigoid
    D'Auria, L
    Fei, PC
    Ameglio, F
    EUROPEAN CYTOKINE NETWORK, 1999, 10 (02) : 123 - 133
  • [23] Resolution in bullous pemphigoid
    Sadik, Christian D.
    Schmidt, Enno
    SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (06) : 645 - 654
  • [24] Eosinophils as putative therapeutic targets in bullous pemphigoid
    Simon, Dagmar
    Borradori, Luca
    Simon, Hans-Uwe
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (12) : 1187 - 1192
  • [25] Proinflammatory Cytokine Gene Polymorphisms in Bullous Pemphigoid
    Tabatabaei-Panah, Pardis-Sadat
    Moravvej, Hamideh
    Sadaf, Zahra
    Babaei, Hadis
    Geranmayeh, Maryam
    Hajmanouchehri, Sedigheh
    Karimi, Ahmad
    Sajjadi, Fatemeh
    Arghand, Fereshteh
    Ludwig, Ralf J.
    Witte, Mareike
    Akbarzadeh, Reza
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [26] Presence of immunoglobulin E-expressing antibody-secreting cells in the dermis close to bullous pemphigoid lesions
    Budair, Fatimah
    Kambe, Naotomo
    Kogame, Toshiaki
    Hirata, Masahiro
    Takimoto-Ito, Riko
    Mostafa, Alshimaa
    Nomura, Takashi
    Kabashima, Kenji
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (04)
  • [27] Bullous pemphigoid
    Beneton-Benhard, Nathalie
    PRESSE MEDICALE, 2010, 39 (10): : 1058 - 1065
  • [28] Omalizumab therapy for bullous pemphigoid
    Yu, Kenneth K.
    Crew, Ashley B.
    Messingham, Kelly A. N.
    Fairley, Janet A.
    Woodley, David T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 71 (03) : 468 - 474
  • [29] Biological treatment for bullous pemphigoid
    Oren-Shabtai, Meital
    Mimouni, Daniel
    Nosrati, Adi
    Atzmony, Lihi
    Kaplan, Baruch
    Barzilai, Aviv
    Baum, Sharon
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [30] Emerging treatments for bullous pemphigoid
    Garrido, Pedro Miguel
    QueiroS, Catarina Soares
    Travassos, Ana Rita
    Borges-Costa, Joao
    Filipe, Paulo
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (02) : 649 - 661